Caramel color in colas may increase risk of cancer
the ONA take:
People who drink sodas that contain caramel color, a popular ingredient in dark colas, are likely exposing themselves to carcinogens that contribute to development of cancer, according to a new study published in PLOS ONE.
Johns Hopkins researchers led by Keeve Nachman, PhD, at the Center for a Livable Future (CLF) conducted a follow-up study to a 2014 Consumer Reports that analyzed 11 different soft drinks for 4-methylimidazole (4-MEI) concentrations, a possible human carcinogen that is formed during the manufacture of caramel color.
They modeled exposure to 4-MEI as related to routine soft drink consumption levels in the U.S. The study also paired results with beverage consumption data from the National Health and Nutrition Examination Survey (NHANES) to measure for population risk and cancer burden.
They found that 4-MEI levels varied substantially across soda brands, even for the same type of beverage. Additionally, they found a geographic difference in 4-MEI levels, with soft drinks products sold in California containing lower levels than samples observed outside the state.
There is currently no federal limit on 4-MEI in food or beverages. However, Consumer reports petitioned the FDA to urge beverage makers in taking steps to protect public health.
“This new analysis underscores our belief that people consume significant amounts of soda that unnecessarily elevate their risk of cancer over the course of a lifetime,” said Urvashi Rangan, PhD, executive director at the Consumer Reports Food Safety and Sustainability Center.
People who drink sodas that contain caramel color are likely exposing themselves to carcinogens that contribute to development of cancer.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|